Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pixantrone + rituximab versus gemcitabine + rituximab in relapsed aggressive B-cell non-Hodgkin lymphoma
2012-001790-86Phase 3Completed
- Sponsor
- CTI BioPharma Corp.
- Start
- Jul 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in mature B-cell lymphoma, diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) comparing Pixantrone + rituximab with Gemcitabine + rituximab (2 arms). Primary endpoint: Progression-free survival. Started Jul 2012; status: completed.
02
Drugs
pixantronerituximabgemcitabine
03
Conditions
mature B-cell lymphomadiffuse large B-cell lymphoma (DLBCL)follicular lymphoma (FL)
Beyond the preview
Go deeper on 2012-001790-86.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-001790-86.